Research programme: Antibody drug conjugate therapeutics- NBE Therapeutics

Drug Profile

Research programme: Antibody drug conjugate therapeutics- NBE Therapeutics

Alternative Names: CD19 targeting antibody drug conjugates- NBE Therapeutics; CD30 targeting antibody drug conjugates- NBE Therapeutics; HER2 targeting antibody drug conjugates- NBE Therapeutics; NBE 001- NBE Therapeutics; NBE 002- NBE Therapeutics; PNU-159682-brentuximab antibody drug conjugate - NBE Therapeutics; PNU-159682-cAC10 antibody drug conjugate - NBE Therapeutics; PNU-159682-trastuzumab antibody drug conjugate - NBE Therapeutics

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator NBE-Therapeutics
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Anaplastic large cell lymphoma; B cell lymphoma; Breast cancer; Hodgkin's disease; Leukaemia; Lung cancer; Multiple myeloma; Ovarian cancer
  • Research Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017) (Parenteral)
  • 29 Aug 2016 Antibody drug conjugate targeting CD19 out-licensed to an undisclosed organisation
  • 29 Aug 2016 Early research in Pancreatic cancer in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top